Robert F. Kushner

Nov 4, 2024 | healio.com | Scott Buzby |Erik Swain |Donna Ryan |Robert F. Kushner

You've successfully added Obesity in Endocrinology to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: SELECT cemented weight pharmacotherapy as a path for CV risk reduction.

Jul 22, 2024 | jamanetwork.com | Kimberly A. Gudzune |Robert F. Kushner

Abstract Importance  Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations  AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action.

Apr 4, 2024 | mdedge.com | Robert F. Kushner

Publish date: April 4, 2024 Is lifestyle counseling needed with the more effective second-generation nutrient-stimulated, hormone-based medications like semaglutide and tirzepatide? If so, how intensive does the counseling need to be, and what components should be emphasized? These are the clinical practice questions at the top of mind for healthcare professionals and researchers who provide care to patients who have overweight and/or obesity. This is what we know.

Mar 29, 2024 | medscape.com | Robert F. Kushner

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. My Alerts You have already selected for My Alerts Add Other Topics Click the topic below to receive emails when new articles are available. Add You've successfully added to your alerts. You will receive email when new content is published. Manage Email Alerts

Jan 11, 2024 | onlinelibrary.wiley.com | Robert F. Kushner |Thomas Wadden

LETTER TO THE EDITOR Response to “The safety of semaglutide in patients with depression and obesity” Robert F. Kushner,  Corresponding Author Robert F. Kushner Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA Correspondence Robert F. Kushner, Northwestern University Feinberg School of Medicine, Division of Endocrinology, 645 N. Michigan Ave., Suite 530, Chicago, IL 60611, USA. Email: [email protected] for more papers by this authorThomas A.